Moderna shares will likely remain under scrutiny after plunging nearly 17% Monday as the embattled drug maker slashed its ...

Share prices of Moderna (NASDAQ: MRNA) plummeted 58% in 2024, ranking among the worst performers in the S&P 500 index. The ...

Shares of Moderna plunged 20% Monday after the vaccine maker slashed its forecast of full-year 2025 revenue, as sales of its ...

Today’s drop in Moderna’s price moves the company’s stock to its lowest levels since April 2020. Shares now trade 93% lower ...

U.S. equities were mixed at midday, with the Nasdaq losing more than 1% on worries about future Federal Reserve interest-rate ...

The messenger RNA (mRNA) pioneer provided a business and pipeline update at the J.P. Morgan Healthcare Conference on Monday.

Moderna (NASDAQ: MRNA) shareholders have been having a rough time lately. The biotech stock rocketed higher last spring, but ...

Moderna's been anything but a high-flying growth stock in this investor's portfolio. So is it high time he gave up on this ...

Moderna Inc (MRNA) stock saw a decline, ending the day at $33.76 which represents a decrease of $-1.01 or -2.90% from the prior close of $34.77. The stock opened at $34.75 and touched a low of $33.34 ...

Morgan Stanley analyst Terence Flynn lowered the firm’s price target on Moderna (MRNA) to $38 from $70 and keeps an Equal Weight rating on the ...

Moderna now expects 2025 revenue to come in between $1.5 billion and $2.5 billion, most of which will come in the second half of the year.

The S&P 500 ended 0.2% higher on Monday, Jan. 13, 2025, ahead of this week's inflation data and the first wave of earnings ...